Helsinn, the Braglia family pharma, sees some big changes in leadership as it unveils a new R&D strategy
For anyone who’s been paying close attention, Helsinn’s shift to targeted cancer therapies has been a long time coming. But on Thursday, the company officially unveiled its new strategy — and with it, some big structural and leadership changes.
Helsinn is straying away from its success as a cancer supportive care company and turning to a new so-called Fully Integrated Targeted Therapy (FITT) strategy, the Braglia family announced Thursday. Giorgio Calderari, who’s been with the company for the last 36 years, has been tapped to lead the charge as CEO, while Riccardo Braglia steps into his dad’s old role as executive chairman.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.